Información del artículo
El Texto completo está disponible en PDF
References
[1.]
Baldessarini RJ. Chemotherapy in Psychiatry. 3rd ed. New York: Springer Verlag; 2012. In press.
[2.]
R.J. Baldessarini, F.I. Tarazi.
Drug therapy of depression and anxiety disorders and drugs for psychosis and mania.
Goodman and Gilman's the pharmacological basis of therapeutics, 11th ed, pp. 429-500
[3.]
R.J. Baldessarini.
American biological psychiatry and psychopharmacology 1944–1994.
American Psychiatry after World War II (1944–1994), a volume celebrating the 150th anniversary of the founding of the American Psychiatric Association, pp. 371-412
[4.]
L.L. Iversen, S.D. Iversen, F.E. Bloom, R.H. Roth.
Introduction toneuropsychopharmacology.
9th ed, Oxford University Press, (2009),
[5.]
Harris G. Federal research center will help develop medicines. New York Times, January 23, 2011, p. 1 y 21.
[6.]
N. Agarwal, J.D. Port, M. Bazzocchi, P.F. Renshaw.
Update on the use of MR for assessment and diagnosis of psychiatric diseases.
Radiology, 255 (2010), pp. 23-41
[7.]
D.M. Dick, B. Riley, K.S. Kendler.
Nature and nurture in neuropsychiatric genetics: where do we stand?.
Dialogues Clin Neurosci, 12 (2010), pp. 7-23
[8.]
J. Kirchheiner, A. Seeringer, R. Viviani.
Pharmacogenetics in psychiatry –-a useful clinical tool or wishful thinking for the future?.
Curr Pharm Des, 16 (2010), pp. 136-144
[9.]
M.E. Shenton, T.J. Whitford, M. Kubicki.
Structural neuroimaging in schizophrenia: from methods to insights to treatments.
Dialogues Clin Neurosci, 12 (2010), pp. 317-332
[10.]
A.C. Viguera, R.J. Baldessarini, J.M. Hegarty, D. Van Kammen, M. Tohen.
Clinical risk following abrupt and gradual withdrawal of maintnenance neuroleptic treatment.
Arch Gen Psychiatry, 54 (1997), pp. 49-55
[11.]
R.J. Baldessarini, L. Tondo, G.L. Faedda, et al.
Latency, discontinuation, and re-use of lithium treatment.
Lithium in neuropsychiatry: the comprehensive guide, pp. 465-481
[12.]
R.J. Baldessarini, L. Tondo, C. Ghiani, B. Lepri.
Illness risk following rapid versus gradual discontinuation of antidepressants.
Am J Psychiatry, 167 (2010), pp. 934-941
[13.]
D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, W.S. Richardson.
Evidence based medicine: what it is what it isn’t.
BMJ, 312 (1996), pp. 71-72
[14.]
J. Fawcett, R.L. Barkin.
Efficacy issues with antidepressants.
J Clin Psychiatry, 58 (1997), pp. 32-39
[15.]
A. Cipriani, T.A. Furukawa, G. Salanti, J.R. Geddes, J.P. Higgins, R. Chur- chill, et al.
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta- analysis.
Lancet, 373 (2009), pp. 746-758
[16.]
P. Bech.
Is the antidepressive effect of second- generation antidepressants a myth?.
Psychol Med, 40 (2010), pp. 181-186
[17.]
S. Leucht, D. Arbter, R.R. Engel, W. Kissling, J.M. Davis.
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.
Molecular Psychiatry, 14 (2009), pp. 429-447
[18.]
A. Yildiz, E. Vieta, S. Leucht, R.J. Baldessarini.
Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.
Neuropsychopharmacology, 36 (2011), pp. 375-389
[19.]
P. Salvatore, R.J. Baldessarini, M. Tohen, H.M. Khalsa, J.P. Sanchez-Toledo, C.A. Zarate Jr., et al.
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients.
J Clin Psychiatry, 70 (2009), pp. 458-466
[20.]
P. Salvatore, R.J. Baldessarini, M. Tohen, H.M. Khalsa, J. Perez Sanchez-Toledo, et al.
McLean-Harvard International first-episode project: Two-year Stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients.
J Clin Psychiatry, (2010),
[21.]
Vázquez G, Baldessarini RJ, Yildiz A, Tamayo J, Tondo L, Salvatore P. Multi-site international collaborative clinical trials in mania: commentary. Int J Neuropsychopharmacol. 2011. In press.
[22.]
E. Vieta.
Terciarismo en psiquiatría: el Programa de Trastornos Bipolares del «Clínic» de Barcelona.
Rev Psiquiatr Salud Ment (Barc), (2011), pp. 1-4
[23.]
A.S. Kemp, N.E. Schooler, A.H. Kalali, L. Alphs, R. Anand, G. Awad, et al.
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?.
Schizophrenia Bull, 36 (2010), pp. 504-509
[24.]
A. Yildiz, E. Vieta, M. Tohen, R.J. Baldessarini.
Placebo effects in treatment trials for acute mania.
Int J Neuropsychopharmacol, (2011),
[25.]
L. Eisenberg.
Mindlessness and brainlessness in psychiatry.
Br J Psychiatry, 148 (1986), pp. 497-508
[26.]
S.N. Ghaemi.
The rise and fall of the biopsychosocial model: reconciling art and science in psychiatry.
Johns Hopkins University Press, (2010),
Copyright © 2011. SEP y SEPB